N/A N=51 CVT-ISR First in Human Trial for Coronary In-Stent Restenosis
In-stent Restenosis
Primary: The Primary Safety Endpoint for the CVT-ISR Study: Freedom From Target Lesion Failure (TLF) Rate — 4; 1; 0; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=81 Paclitaxel Releasing Balloon in Patients Presenting With In-Stent Restenosis
In-stent Coronary Artery Restenosis
Primary: In-stent Late Lumen Loss — 0.07 mm
Phase 2 N=41 PERVIDEO I Registry, The Lutonix Paclitaxel-Coated Balloon Catheter for the Treatment of Coronary In-Stent Restenosis
In-Stent Restenosis
Primary: Percent Diameter Stenosis (%DS) in the Analysis Segment — 36.0 Percentage stenosis of vessel diameter
N/A N=499 STELLAREX: ILLUMENATE Global and In-Stent Restenosis (ISR)
Peripheral Arterial Disease
Primary: Percentage of Participants With Freedom From Device and Procedure-related Death and Freedom From Target Limb Major Amputation and Clinically-driven Target Lesion…
N/A N=108 In-Stent Restenosis Post-Approval Study
Peripheral Artery Disease · Vascular Disease
Primary: Primary Effectiveness — 0.715 Probability
N/A N=86 Wall Shear Stress and Neointimal Healing Following PCI in Angulated Coronary Vessels
Coronary Artery Disease
Primary: In Stent Mean Cross-sectional Area of Neo-intimal Tissue Coverage — 1.381; 0.949 mm^2
Phase 2 N=12 Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis
Coronary Restenosis
Primary: Phase I: Number of Participants With Dose-limiting Toxicities — 0; 0; 0; 0 participants
N/A N=29 JetStream (JS) Atherectomy in Femoropopliteal In-Stent Restenotic Lesions
Restenosis · Peripheral Vascular Disease
Primary: Acute Procedural Success — 29 limbs
Phase 3 N=252 Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis
Peripheral Arterial Disease
Primary: Freedom From Target Lesion Revascularization (TLR) — 123; 43 # of participants free from TLR
N/A N=68 Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension
Renal Artery Stenosis · Hypertension, Renovascular
Primary: Primary Patency — 66 Subject-lesions — p=<.0001
Phase 3 N=100 Study of the 2.25mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions
Coronary Artery Disease
Primary: Percentage of Participants Who Experienced In-lesion Restenosis as Measured by Quantitative Coronary Angiography (QCA) at 6 Months Post-procedure — 16.9 Percentage of…
Phase 4 N=200 Study of Oral Rapamycin Plus Bare Metal Stents vs Drug Eltuting Stents
Coronary Heart Disease · Coronary Restenosis
Primary: Differences in Costs Between Two Revascularization Strategies for de Novo Coronary Lesions. — 5483; 7658.2 US dollars — p=<0.05
N/A N=82 Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis
Femoral Artery Stenosis · Femoral Artery Occlusion · Restenosis
Primary: Percentage of Participants With Primary Patency at 1 Year — 67.0; 49.5 Percentage of Participants
Phase 4 N=114 Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting
CVD
Primary: Number of Participants With Occlusion and Restenosis at One Year — 58; 56 participants
N/A N=60 Rotational Atherectomy Combined With Cutting Balloon to Optimize Stent Expansion in Calcified Lesions
Coronary Artery Disease · Atherosclerosis
Primary: Minimum Stent Area After Percutaneous Coronary Intervention — 6.7; 6.9 mm^2
N/A N=1,334 Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
Coronary Artery Disease · Atherosclerosis, Coronary · Myocardial Ischemia
Primary: Percentage of Participants With Target Lesion Failure (TLF) at 12 Months Post-Index Procedure by Bayesian Estimation — 6.32; 8.90 Percentage of participants
N/A N=275 FLUENCY® PLUS Endovascular Stent Graft for In-stent Restenosis
Restenosis
Primary: Percentage of Participants With Access Circuit Primary Patency (ACPP) That is Superior for FLUENCY® PLUS Endovascular Stent Graft (Following Percutaneous Transluminal…
Phase 4 N=479 Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Sten for Coronary Lesions in Acute Myocardial Infarction
Myocardial Infarction
Primary: Device-oriented Composite Outcome — 12; 13 participants
Phase 4 N=597 Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty
Saphenous Vein Graft Atherosclerosis
Primary: Number of Participants With Target Vessel Failure (TVF), Defined as the Composite of Cardiac Death — 16; 17 Participants
Phase 3 N=2,651 Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
Coronary Artery Disease · Angina Pectoris
Primary: Kaplan-Meier Estimates for Time From Randomization to First Occurrence of Ischemia-driven Revascularization or Ischemia-driven Hospitalization Without Revascularization…
Phase 4 N=888 Clinical Investigation for Everolimus Drug Eluting Stent
Coronary Arterial Disease (CAD)
Primary: 888 Number of Participants With Major Adverse Cardiac Events (MACE) at 30 Days — 0 participants
N/A N=60 JetStream Atherectomy for the Treatment of In-stent Restenosis
Femoropopliteal In-stent Restenosis
Primary: Percentage of Participants With Target Lesion Revascularization (TLR) — 12 Participants
N/A N=222 EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions
Coronary Artery Disease (CAD) · Chronic Total Occlusion (CTO)
Primary: Number of Participants With Stent-related: Major Adverse Cardiac Events (MACE) (Per ITT Set) — 39 Participants
N/A N=56 Resolute Integrity US Extended Length Sub-Study(RI US XL)
Coronary Artery Disease
Primary: Composite Rate of Cardiac Death and Target Vessel Myocardial Infarction (MI) — 4 Participants
N/A N=230 An Evaluation of the Commercially Available Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System
Coronary Artery Disease
Primary: Composite Rate of Cardiac Death and Target Vessel Myocardial Infarction (MI) — 3.6 percentage of participants
Phase 4 N=20 Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging
Peripheral Artery Disease · Vascular Disease · Critical Limb Ischemia
Primary: Change in Percent Wall Volume (PWV) — 12.3; 3.9 Percent Wall Volume — p=0.22
N/A N=1,919 Study of BioNIR Drug Eluting Stent System in Coronary Stenosis
Coronary Artery Stenosis
Primary: Target Lesion Failure (TLF) — 5.4; 5.4 percentage of TLF
N/A N=214 Outcome of Coronary High Angulated Bifurcation Lesions Treated With Kissing Ballooning or Sequential Ballooning Techniques
Stable Angina
Primary: Percentage of Participants With Major Adverse Cardiac Events(MACE) — 1.72; 6.86 percentage of participants
N/A N=500 Physiologic Assessment of Coronary Stenosis Following PCI
Coronary Artery Disease · Coronary Stenosis · Angina, Unstable
Primary: Number of Participants With Residual Ischemia (iFR <0.90) — 112 participants
N/A N=82 TurboPower + DCB Treatment of Femoropopliteal De Novo/ Restenotic and In-Stent Restenosis Lesions
Peripheral Arterial Disease
Primary: Number of Participants Free From Target Lesion Revascularization (TLR) — 52 Participants